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The purpose of this phase II trial was to determine the efficacy and safety of the XELOX (capecitabine/oxaliplatin) regimen as first-
line therapy in the elderly patients with metastatic colorectal cancer (MCRC). A total of 50 patients with MCRC aged X70 years
received oxaliplatin 130mgm
 2 on day 1 followed by oral capecitabine 1000mgm
 2 twice daily on days 1–14 every 3 weeks.
Patients with creatinine clearance 30–50mlmin
 1 received a reduced dose of capecitabine (750mgm
 2 twice daily). By intent-
to-treat analysis, the overall response rate was 36% (95% CI, 28–49%), with three (6%) complete and 15 (30%) partial responses. In
total, 18 patients (36%) had stable disease and 14 (28%) progressed. The median times to disease progression and overall survival
were 5.8 months (95% CI, 3.9–7.8 months) and 13.2 months (95% CI, 7.6–16.9 months), respectively. Capecitabine was well
tolerated: grade 3/4 adverse events were observed in 14 (28%) patients: 11 (22%) diarrhoea, eight (16%) asthenia, seven (14%)
nausea/vomiting, three (6%) neutropenia, three (6%) thrombocytopenia, and two (4%) hand–foot syndrome. There was one
treatment-related death from diarrhoea and sepsis. In conclusion, XELOX is well tolerated in elderly patients, with respectable
efficacy and a meaningful clinical benefit response. Given its ease of administration compared with combinations of oxaliplatin with
5-FU/LV, it represents a good therapeutic option in the elderly.
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Colorectal cancer (CRC) is the second most common cause of
death from cancer in industrialised countries (Jemal et al, 2003)
and its incidence increases with age (Gatta et al, 1998). Because of
a progressively ageing population, it can be expected that the
number of elderly with CRC will increase significantly in coming
decades. However, chemotherapy is used less frequently in the
elderly than in other age groups, in both the adjuvant (Potosky
et al, 2002) and metastatic (Simmonds and Best, 1999; Sundarajan
et al, 1999) settings. Factors that influence the resistance to use
chemotherapy in the elderly include: a general lack of studies in
this age group; the fear that the progressive reduction of functional
reserve that occurs in various organs with ageing might increase
the susceptibility of the elderly to adverse effects that can reduce
quality of life, particularly diarrhoea, mucositis, and myelo-
suppression (Balducci and Extermann, 2000) and comorbidity,
which makes it difficult or impossible to use chemotherapy (De
Marco et al, 2000).
Oxaliplatin and irinotecan are now established as first-line
agents in the treatment of metastatic CRC (MCRC). The addition of
oxaliplatin to 5-FU/leucovorin (LV) in first-line therapy has
allowed an increase in response rates and time to disease
progression (TTP) as compared to 5-FU/LV alone (de Gramont
et al, 2000; Douillard et al, 2000; Giacchetti et al, 2000; Saltz et al,
2000; Grothey et al, 2002). In addition, it has been found recently
that the combination of oxaliplatin with infusional 5-FU/LV
significantly increases response rate, TTP, and overall survival as
compared to the combination of irinotecan with bolus 5-FU/LV
(Goldberg et al, 2004). These regimens have the inconvenience
of being based on the requirement for continuous infusion,
which necessitates permanent venous access and the need to
carry infusion apparatus/fluids. This increases the risk of
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scatheter-related complications, such as infections (Clark and
Raffin, 1990) or thromboembolism (Prandoni and Bernardi,
1990; Verso and Agnelli, 2003).
Oral chemotherapy avoids the costs and inconveniences
associated with continuous infusions and is preferred to i.v.
therapy given equal efficacy (Liu et al, 1997; Borner et al, 2002b).
Capecitabine (Xeloda
s; Hoffmann-La Roche Inc., Nutley, NJ,
USA) is an orally administered fluoropyrimidine designed to
deliver 5-FU to tumour tissue (Miwa et al, 1998; Schu ¨ller et al,
2000). Large-scale, phase III trials have shown that capecitabine
single-agent therapy is at least as effective and well tolerated as
5-FU/LV as first-line treatment for MCRC (Hoff et al, 2001; Van
Cutsem et al, 2001) or as adjuvant therapy for stage III colon
cancer (Scheithauer et al, 2003; Twelves et al, 2005). Furthermore,
these trials showed that capecitabine had similar, favourable
efficacy and safety in patients o65 or X65 years. Various phase II/
III studies have shown similar efficacy and safety for combination
of oxaliplatin with either oral capecitabine or infusional 5-FU/LV
(Borner et al, 2002a; Zeuli et al, 2003; Cassidy et al, 2004; Shields
et al, 2004, Arkenau et al, 2005; Ducreux et al 2005; Sastre et al,
2005), although experience with these regimens in the elderly is
very limited in these studies, and usually excluded those 475
years. In fact, the vast majority of trials of any chemotherapeutic
agents in MCRC have not included trials of patients 470 years.
Given the characteristics of this combination with respect to
efficacy, safety, and ease of administration, the use of capecitabine/
oxaliplatin would be very attractive to use in the general
population and particularly in the elderly in whom chemotherapy
is usually restricted. Thus, the aim of our study was to analyse the
efficacy and safety of the combination of capecitabine and
oxaliplatin (XELOX) in patients X70 years of age with advanced
CRC.
PATIENTS AND METHODS
Patient population
Patients were required to be ambulatory and have an Eastern
Cooperative Oncology Group (ECOG) performance status p2,
with a life expectancy of at least 3 months. All patients had
measurable disease defined by the presence of at least one
unidimensionally measurable lesion (RECIST criteria) (Therasse
et al, 2000) by computed tomography scan. Pleural effusion,
ascites, osteoblastic lesions, or previously irradiated lesions were
not accepted as measurable disease.
Patients who had received prior adjuvant 5-FU-based chemo-
therapy were eligible if they had been disease free for at least 6
months after the completion of therapy. Patients who had received
radiotherapy were eligible if there was at least one measurable
lesion outside the radiation field. Other inclusion criteria were
adequate haematological function (granulocyte count X2 10
9l
 1
and platelets 4100 10
9l
 1); adequate hepatic function (serum
bilirubin o1.25  the upper normal limit (UNL), glutamic
oxaloacetic transaminase (SGOT), and glutamic pyruvic transami-
nases (SGPT) values o2.5  UNL in the absence of hepatic
metastases or o5  UNL in the presence of metastasis); alkaline
phosphatase o2.5  UNL in the absence of hepatic metastases or
o 5  UNL or 10  UNL in the presence of hepatic or bone
metastases and adequate renal function (creatinine clearance
X30mlmin
 1). All patients provided written informed consent
according to local ethical committee directives.
Patients with operable metastatic disease were excluded from
the study. Other exclusion criteria were as follows: clinically
significant cardiac disease or myocardial infarction within the last
12 months; lack of physical integrity of the upper gastrointestinal
tract or malabsorption syndrome; peripheral neuropathy of
National Cancer Institute (NCI) grade 2 or greater; prior therapy
with capecitabine, oxaliplatin, or irinotecan; known brain or
meningeal metastases; and history of other malignancy, except
basal cell carcinoma or adequately treated in situ cervical
carcinoma.
Local research ethics committees approved the trial protocol
and all patients provided written informed consent.
Treatment plan
The study regimen consisted of oxaliplatin 130mgm
 2 as 120-min
i.v. infusion on day 1 and oral capecitabine 1000mgm
 2 twice
daily (2000mgm
 2 total daily dose) on days 1–14 every 3 weeks.
In patients with a creatinine clearance of 30–50mlmin
 1, the
dosage of capecitabine was reduced to 750mgm
 2 twice daily
(1500mgm
 2 total daily dose). The dose of capecitabine was
rounded to the next closest dose that could be administered using
a combination of 500- and 150-mg tablets. The two daily doses of
capecitabine were administered 1272h apart, 30min after meals
(breakfast and evening meal), with approximately 200ml of water.
The Cockcroft–Gault formula (Cockcroft and Gault, 1976) was
used to calculate the creatinine clearance between cycles. If
clearance was o30mlmin
 1, treatment was interrupted. Cycles
were repeated every 3 weeks for a minimum of three per patient,
unless disease progressed. Patients with a partial response or stable
disease continued chemotherapy until progression or the devel-
opment of unacceptable adverse events. Patients could also
continue capecitabine monotherapy after discontinuation of
oxaliplatin because of toxicity.
Patients were evaluated for adverse events before each cycle and
graded according to NCI Common Toxicity Criteria (version 2.0).
For hand–foot syndrome, the previously published grading system
was used (Blum et al, 1999). Dose reduction/interruption for
capecitabine according to adverse event grade was performed as
previously described (Blum et al, 1999). The oxaliplatin dose was
reduced by 25% in the event of grade 3 or 4 thrombocytopenia,
grade 4 neutropenia, or any other severe (Xgrade 3) organ
toxicity, and for paresthesiae with pain or functional impairment
47 days, or paresthesiae with pain persistent between cycles. For
paresthesiae with functional impairment persistent between cycles,
oxaliplatin was discontinued. Treatment could be delayed for up to
2 weeks if symptomatic toxicity persisted, the absolute neutrophil
count was lower than 1 10
9l
 1, or the platelet count was lower
than 75 10
9l
 1. Subcutaneous administration of granulocyte
colony-stimulating factor 5mgkgday
 1 on 5 consecutive days was
recommended in the former group of patients. Any patient who
required more than 2 weeks for recovery from adverse reactions
was excluded from the study.
Pretreatment and follow-up evaluation
A diagnostic work-up was performed within 3 weeks prior to the
start of treatment, consisting of a complete clinical history,
physical examination, blood analysis (haematology and complete
biochemistry), and imaging studies as needed (chest X-ray,
computed tomography of the chest, abdomen and pelvis,
abdominal ultrasound, and bone scan). The Charlson comorbidity
scale (Charlson et al, 1987), Katz Activity of Daily Living (ADL)
index (Katz et al, 1963), and Lawton Instrumental Activity of Daily
Living (IADL) index (Lawton, 1998) were used in patient
assessment. Patients’ ECOG performance status and weight were
also recorded. An ECG was performed in all patients prior to
receiving study treatment. Symptom assessment, physical exam-
ination, and blood biochemistry were repeated before each
treatment cycle. Tumour measurements were taken every three
cycles or sooner if clinically indicated.
Patients and/or caregivers were given a card indicating the
number of pills that they were to take per day: they were asked to
record the dose actually taken and give the card back to the doctor
at the next visit.
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sResponse criteria
Patients were evaluated clinically at least every 3 weeks and
radiographically every 9 weeks. The same evaluation modality was
used throughout the study. The RECIST response guidelines were
used (Therasse et al, 2000), defining all responses after at least 9
weeks of therapy as follows: complete response (CR), partial
response (PR), stable disease (SD), or progressive disease (PD). We
defined disease control as the sum of patients achieving a CR, PR, or
SD. Confirmation of all responses was required after 4 weeks. The
TTP was estimated from the dates of the first course of treatment to
the first documentation of disease progression. Survival was
calculated by the same method from the date of the first cycle of
treatment until the date of death or last known follow-up.
Symptoms assessment
An assessment of clinical benefit was determined from a composite
of pain intensity, analgesic consumption, ECOG performance
status, weight loss, and the presence of anorexia and asthenia. The
same doctor for each patient assessed ECOG performance status
and symptoms before each chemotherapy cycle. Patients entered a
pain stabilisation run-in period to establish baseline measures.
Pain was assessed with the Memorial Pain Assessment Card
(MPAC) (Fishman et al, 1987). Asthenia and anorexia were
assessed using a visual analogue scale (VAS) of 0–100. In addition,
patients’ weight was measured at each visit. Patients were
considered to be evaluable for palliative benefits when they
initially had one of the following signs or symptoms: an ECOG
performance status X1; an MPAC score X20; baseline analgesic
consumption of X10 morphine equivalents mgday
 1; score on the
VAS for anorexia and/or asthenia of X20; or weight loss 410%
during the previous 6 months.
Symptom improvement was defined as an improvement of at
least one score from baseline in ECOG performance status; 5%
weight gain from baseline (patients with oedema, ascites, or pleural
effusion were excluded from this category); or an improvement of
X50% from baseline in disease-related symptoms (pain, use of
analgesics, anorexia, and asthenia) and analgesic consumption
(measured weekly in morphine-equivalent milligrams). Each of
these improvements had to be sustained for at least 4 weeks
(Cocconi et al, 1998).
Statistical methods
The primary end point of the trial was to determine the activity of
the XELOX regimen in the intent-to-treat population. Secondary
objectives were the safety profile, clinical benefit, TTP, and overall
survival. Dose intensity was calculated for each patient from the
total dose of capecitabine and oxaliplatin administered during the
entire course of treatment and expressed as the mean drug dose in
mgm
 2week
 1.
An optimal two-stage design as described by Simon (1989) was
used. A true response probability of 40% or greater was considered
to be of interest, while further testing of the regimen would not be
pursued if the response probability was 20% or lower. In the first
stage, a total of 13 patients were included and at least four
responses (CR or PR) were required to continue to the second
stage. In the second stage, 30 additional patients were included
plus 10% to allow for losses. Univariate analysis was used
to compare the rate of grade 3/4 adverse events according to age
(70–79 years vs X80 years), gender, creatinine clearance (o50 vs
X50mlmin
 1), Charlson comorbidity scale (0 vs X1), ECOG
performance status (0 vs X1), and ADL and IADL (independent vs
dependent). Wilcoxon’s signed-rank test (to compare quantitative
variables) and Fisher’s exact test (to compare percentages) were
used. Overall survival and TTP were calculated using the Kaplan–
Meier method.
RESULTS
Patient characteristics
From January 2003 to September 2003, 54 patients from 11 centres
were included. Four patients were excluded from analysis because
they did not meet all selection criteria. Their mean age was 76
(range, 70–82) years. The demographic and clinical characteristics
of the patients are shown in Table 1, while Table 2 shows their
functional assessments. One-third of patients were metastatic at
the time of diagnosis, although only one-third had received prior
adjuvant therapy. In five patients (10%), the primary tumour was
not resected. The median time from the primary diagnosis of CRC
to inclusion was 14.6 months. Regarding symptoms, 38 patients
had significant symptoms at baseline evaluation, which included
asthenia (56%), pain (40%), and anorexia (28%). In total, 28
patients (56%) had comorbid conditions, mainly hypertension,
arthritis, obstructive lung disease, peptic ulcer disease, diabetes,
coronary insufficiency, and cardiovascular conditions. Comorbid-
ity was present in 20 (40% of) patients when using the Charlson
scale (Charlson et al, 1987).
Treatment duration
A total of 286 cycles of treatment were administered, with a median
of five per patient (range 1–8 cycles). Eight (16%) patients
received less than three cycles of XELOX, due to disease
progression (n¼2, 4%), because of adverse events (n¼3, 6%),
treatment-related death (n¼1, 2%), lost to follow-up (n¼1, 2%),
and refusal to continue treatment (n¼1, 2%). Nevertheless, all of
Table 1 Patient characteristics at study entry (n¼50)
Characteristic Patients (%)
Age (years)
70–75 56
76–79 32
X80 12
Gender
Male 72
Female 28
ECOG performance status
05 2
14 6
22
Location of primary tumour
Colon 68
Rectum 28
Both 4
No. of metastatic sites
17 4
X22 6
Differentiation
Well differentiated 10
Moderately differentiated 60
Poorly differentiated 18
Undetermined/unknown 12
Sites of metastasis
Liver 64
Lung 32
Lymph node 14
Other 24
ECOG¼Eastern Cooperative Oncology Group.
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sthe patients enrolled were considered evaluable for both efficacy
and safety. A total of 23 (46%) patients experienced treatment
delays during the study for causes unrelated to the treatment
(n¼10, 20%), haematological adverse events (n¼5, 10%), and
nonhaematological adverse events (n¼8, 16%). The median dose
intensity of capecitabine was higher for patients with creatinine
clearance 450mlmin
 1 (9.22gm
 2week
 1), and for the remain-
ing 14 patients with creatinine clearance between 30 and
50mlmin
 1 (7.68gm
 2week
 1). These doses correspond to 86
and 98% of the predicted dose intensity, respectively. The median
dose intensity of oxaliplatin was 39.8mgm
 2week
 1, which
corresponded to 92% of the predicted dose intensity. During the
course of their disease, 12 patients (24%) needed a central venous
access: two during the XELOX treatment, six during the second-
line treatment, and the rest of the patients after completion of
chemotherapy for symptomatic treatment purposes.
Efficacy
The assessment of response was performed on the ITT population
of 50 eligible patients. Of these, three patients (6% of the eligible
population) had a CR and 15 (30%) a PR. A total of 18 patients
(36%) maintained SD and 14 (28%) had PD. The overall response
rate was 36% (95% confidence interval (CI), 23–49%). There
was no relationship between the rate of response and the
location of metastases, ECOG performance status, ADL, IADL, or
patients’ age.
The median TTP was 5.8 months (95% CI, 3.9–7.8 months;
Figure 1), median overall survival was 13.2 months (95% CI,
7.6–16.9 months; Figure 2), and the actuarial survival per year was
51% (95% CI, 37–65%). Second-line chemotherapy based on
irinotecan was subsequently administered in 12 patients (24%).
Of the 50 enrolled patients, 38 were evaluable for symptoms or
ECOG score response. The remaining 12 patients were not
evaluable for the following reasons: ECOG¼0, MPAC score
o20, or VAS for anorexia and asthenia o20. Clinical benefit
responses are summarised in Table 3. Overall, 16 patients (42%;
95% CI, 26.7–59.6%) obtained an improvement in ECOG score
and/or at least one symptom without worsening in other
symptoms or ECOG score. The median duration of this improve-
ment was 5.3 months (95% CI, 2–12 months).
Safety
Treatment was generally well tolerated. In all, 32 patients (64%)
had an adverse event, usually grade 1/2. The main adverse events
were gastrointestinal and haematological (Figure 3). A total of 14
patients (28%) had grade 3/4 adverse events: 11 (22%) diarrhoea,
eight (16%) asthenia, seven (14%) nausea/vomiting, three (6%)
neutropenia, three (6%) thrombocytopenia, two (4%) hand–foot
syndrome, and one each (2%) with anaemia, mucositis, and
sensory neuropathy, respectively. In a patient with a protocol
violation, there was one treatment-related death due to diarrhoea
Table 2 Functional assessments at entry (n¼50)
Functional assessment Patients (%)
Activity of daily living index
No dependence 58
Light dependency 24
Moderate dependency 14
Serious dependency 4
Instrumental activity of daily living index
Autonomous 58
Light dependency 30
Moderate dependency 8
Serious dependency 4
Charlson comorbidity scale
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sand sepsis: the dose of capecitabine was not reduced to 75% due to
creatinine clearance at 38mlmin
 1.
An exploratory univariate analysis did not detect any relation-
ships between the appearance of grade 3/4 adverse events and age
(70–79 years vs X79 years), gender, ADL, IADL, ECOG status,
comorbidity, or renal function.
DISCUSSION
Currently, MCRC is an incurable disease. Thus, treatment must be
directed at survival prolongation, symptom alleviation, and
improving, or at least maintaining, the patient’s quality of life.
These objectives can be achieved using the administration of less
toxic chemotherapy regimens that are easier to administer and do
not require the patient to be hospitalised repeatedly. With the
elderly, we have to be even more careful in the choice of treatment.
It is necessary to consider other aspects that might influence
tolerability, such as the pharmacokinetic and pharmacodynamic
changes that appear with age (Lichtman, 2004) and comorbidity
(Balducci and Extermann, 2000).
The aim of our study was to analyse the efficacy and safety of the
XELOX regimen in elderly patients with MCRC. Our results, with a
response rate of 36% and a median TTP of 5.8 months, are similar
to those obtained by other authors with capecitabine/oxaliplatin
(Borner et al, 2002a; Zeuli et al, 2003; Cassidy et al, 2004) in series
that excluded patients aged 475 years. In contrast, median overall
survival in our series was 13.2 months, which is somewhat less
than the 17–20 months reached in these other studies (Borner
et al, 2002a; Zeuli et al, 2003; Cassidy et al, 2004). However,
median overall survival was similar to that obtained in studies
performed exclusively in the elderly with MCRC who received
combinations of 5-FU/LV plus oxaliplatin or irinotecan (Aparicio
et al, 2003), or capecitabine plus oxaliplatin (Comella et al, 2005).
It has been noted that the survival of patients with MCRC increases
when they receive three active cytostatic agents (5-FU/LV,
oxaliplatin, and irinotecan) during their disease course (Grothey
et al, 2004; Tournigand et al, 2004). Thus, the shorter survival of
the patients in our series might be attributable to the low
proportion of elderly who received a second line of chemotherapy.
For example, it is clear from this study that irinotecan was not a
widely used second line. The frequent comorbidity that is often
present might also contribute towards this. It would therefore
appear necessary to increase the proportion of elderly to whom
second-line treatment has been added after disease progression,
especially if there is little comorbidity, or little or no ADL/IADL
dependence. It is possible that the increasing availability of new
targeted agents could increase the efficacy of treatment in elderly
patients.
The XELOX regimen was generally well tolerated. In total, 28%
of the patients experienced grade 3/4 adverse events, which is
comparable to the safety described with this capecitabine/
oxaliplatin in other series that included patients who were not
elderly ((Borner et al, 2002a; Zeuli et al, 2003; Cassidy et al, 2004;
Shields et al, 2004). The low rate of grade 3/4 neurotoxicity in our
patients might appear somewhat surprising at only 2%, especially
compared with the 17% reported by Cassidy et al (2004). However,
given that the development of this toxicity depends on the total
accumulated dose of oxaliplatin received during treatment, the low
toxicity in our series can probably be attributed to the reduced
number of treatment cycles received by our patients compared to
the series of Cassidy et al (2004) (median 4.5 vs 8 cycles,
respectively). On the other hand, the proportion of the elderly in
our study that developed grade 3/4 adverse events was similar to
the 29% reported in another study performed exclusively in the
elderly and which also used a capecitabine/oxaliplatin regimen, in
which the dose of subsequent cycles was increased as a function of
tolerability by the patient (Comella et al, 2005).
The good tolerability of the XELOX regimen in our series might,
in part, be due to the dose of capecitabine used, which was
adjusted for each cycle as a function of creatinine clearance
(Gieschke et al, 2003; Feliu et al, 2005). We believe that this is
important in the elderly. Moreover, the only toxic death in our
study occurred in a patient where the dose was not appropriately
adjusted because of his low creatinine clearance. The safety of
XELOX was clearly better than when using combinations of 5-FU/
LV plus oxaliplatin in the elderly with MCRC: grade 3/4 adverse
events occurred in 28% of patients in our series compared to
42–80% in series that received 5-FU/LV/oxaliplatin (Aparicio et al,
2003; Figer et al, 2004). Of particular note is the high rate of grade
3/4 neutropenia that is seen with 5-FU/LV/oxaliplatin regimens,
which varies in the elderly between 30 and 55% according to the
series considered (Giacchetti et al, 2000; Baretta et al, 2001;
Aparicio et al, 2003; Mattioli et al, 2003; Figer et al, 2004), whereas
this adverse event was detected in o10% of patients with
capecitabine/oxaliplatin (Borner et al, 2002a; Zeuli et al, 2003;
Cassidy et al, 2004; Shields et al, 2004; Arkenau et al, 2005).
Additionally in our study, we did not encounter any relationship
between toxicity and certain factors that are generally presumed to
be capable of predisposing to greater toxicity, such as female
gender (Macdonald, 2002) comorbidity (Balducci and Extermann,
2000), performance status, etc. However, we acknowledge that the
small number of patients means that our study might be
insufficiently powered to detect these relationships.
In addition to the potential efficacy and safety advantages of
replacing 5-FU with capecitabine, it is important to consider the
ease of oral administration, which avoids the possible complica-
tions and inconveniences associated with the use of infusion
Table 3 Effect of the treatment on performance status and symptom
(n¼38)
Patients (%)
Parameter Improvement Stabilisation Worsening
ECOG performance status 20 60 20
Pain 23 63 14
Anorexia 26 54 20
Asthenia 37 37 26
Weight loss 26 60 14
ECOG¼Eastern Cooperative Oncology Group.
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Figure 3 Adverse events by NCI-CTC grade (n¼50).
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Prandoni and Bernardi, 1990; Verso and Agnelli, 2003). Also, the
number of hospital visits can be reduced considerably to once
every 3 weeks with XELOX, when the patient is routinely reviewed,
oxaliplatin administered, and capecitabine dispensed. This might
prove especially interesting in elderly patients, who usually require
the assistance of a family member or helper to get to hospital. It is
still important for patients to receive good quality educational
materials and to have regular phone contact with their nurse/
physician. Patients with dependency for the daily activities of life
may still require a caregiver who takes full responsibility of
administering treatment and the early detection of adverse events.
Furthermore, the addition of targeted therapy with bevacizumab
can be conveniently integrated into the 3-weekly XELOX regimen
with little impact on regimen convenience.
In summary, the results of our study show that the XELOX
regimen represents a good therapeutic option in the fit elderly and
in the patient partially dependent and with little severe comorbid-
ity. In addition, it appears safer than that previously reported in
studies with 5-FU/LV plus oxaliplatin, especially in the elderly.
While we do not have available the results of phase III studies in
the elderly comparing the efficacy and tolerability of the XELOX
regimen vs 5-FU/LV plus oxaliplatin, its convenience and ease of
administration lead us to conclude that XELOX might be a good
combination.
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